Canada Markets closed

NOXXON Pharma N.V. (ALNOX.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
0.04100.0000 (0.00%)
At close: 05:35PM CEST
Full screen
Previous Close0.0410
Open0.0450
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0380 - 0.0466
52 Week Range0.0380 - 39.7000
Volume10,209,655
Avg. Volume42,936
Market Cap2.783M
Beta (5Y Monthly)2.24
PE Ratio (TTM)N/A
EPS (TTM)-0.2190
Earnings DateApr 28, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.50
  • Business Wire

    TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-A12 GLORIA Phase 1/2 Brain Cancer Clinical Trial

    BERLIN, August 03, 2022--Regulatory News: TME Pharma N.V., (Euronext Growth Paris: ALTME) (Paris:ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the first patient was enrolled and has received their first week of treatment in the GLORIA Phase 1/2 clinical trial expansion arm with NOX‑A12 combined with radiotherapy and the PD-1 immune checkpoint inhibitor pembrolizumab.

  • Business Wire

    TME Pharma Announces Completion of Share Consolidation

    BERLIN, July 27, 2022--Regulatory News: TME Pharma N.V., (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the amendment of the Articles of Association effecting the share consolidation such that every 100 shares with a nominal value of 1 eurocent each were consolidated and converted into 1 new share with a nominal value of 1 euro.

  • Business Wire

    TME Pharma Announces €3.24 Million Financing Under Agreement With Atlas

    BERLIN, July 15, 2022--Regulatory News: TME Pharma N.V., a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today it has executed a transaction with Atlas Special Opportunities, LLC (ASO), for a total consideration of €3.24 million. The transaction will settle in two tranches over the next 2 months. As a result of the transaction, the company will issue 3,300 convertible bonds (including 60 convertible bo